The major role of the Linkage Core will be to genetically assign families, largely, though not exclusively, derived from the Clinical Core, into the appropriate classes. It will be our intention to separate families by genetic analysis into four groups: (1) those with mutations in known genes (synuclein, parkin, tau for example); (2) those which probably have a pathogenic locus on 4p (parsed to Project 1); (3) those which have a pathogenic locus on chromosome 2p (parsed to Project 2) and (4) those which probably have an underlying genetic etiology, elsewhere in the genome. Families with mutation (s) in known genes will be identified by searching for segregation of marker genotypes in affecteds individuals (by both non-parametic haplotype and model-based linkage analysis) in regions formerly liked to parkinsonism/parkinson's disease. Sequencing known genes in probands will identify mutations. Families may be parsed into chromosome 2p and 4p as appropriate by comparison of autosomal dominant affected-only linkage simulation and observed lod scores/haplotype analysis. Further analysis of genetic heterogeneity among putative 2p and 4p linked families, haplotype analysis of cross-over data to prioritize regions for physical mapping (Projects 1&2) and ultimately linkage disequilibrium analysis within minimal """"""""obligate"""""""" regions will be performed. Families excluded by linkage and lack of haplotype sharing among affecteds will be pooled into groups based on their apparent mode of inheritance (AD, AR X-linked, oligogenic/multifactorial), their phenotype (age of onset, clinical presentation, pathology, ethic and geographical origin) for future genetic studies. As new genomic loci/genes for parkinsonism become identified these will be tested by the mechanisms we have outlined. Concomitantly, the Clinical Core will expand the largest families (or ones that have the greatest potential information content for linkage/easiest to ascertain) both genealogically and in terms of sample collection. Power analysis by the Linkage Core will help prioritize family collection. Periodically, when families have been collected that are of sufficient size and statistical likelihood to successfully identify a new locus for Parkinson's disease, a genome search will be performed.

National Institute of Health (NIH)
National Institute of Neurological Disorders and Stroke (NINDS)
Research Program Projects (P01)
Project #
Application #
Study Section
Special Emphasis Panel (ZAG1)
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Mayo Clinic, Jacksonville
United States
Zip Code
Yue, M; Hinkle, K M; Davies, P et al. (2015) Progressive dopaminergic alterations and mitochondrial abnormalities in LRRK2 G2019S knock-in mice. Neurobiol Dis 78:172-95
Sundal, Christina; Fujioka, Shinsuke; Van Gerpen, Jay A et al. (2013) Parkinsonian features in hereditary diffuse leukoencephalopathy with spheroids (HDLS) and CSF1R mutations. Parkinsonism Relat Disord 19:869-77
Boeve, Bradley F (2013) Idiopathic REM sleep behaviour disorder in the development of Parkinson's disease. Lancet Neurol 12:469-82
Fujioka, Shinsuke; Rayaprolu, Sruti; Sundal, Christina et al. (2012) A novel de novo pathogenic mutation in the CACNA1A gene. Mov Disord 27:1578-9
Hinkle, Kelly M; Yue, Mei; Behrouz, Bahareh et al. (2012) LRRK2 knockout mice have an intact dopaminergic system but display alterations in exploratory and motor co-ordination behaviors. Mol Neurodegener 7:25
Graff-Radford, Jonathan; Whitwell, Jennifer L; Trenerry, Max R et al. (2011) Focal brain atrophy in gastric bypass patients with cognitive complaints. J Clin Neurosci 18:1671-6
Puschmann, Andreas; Wszolek, Zbigniew K (2011) Diagnosis and treatment of common forms of tremor. Semin Neurol 31:65-77
Winner, B; Melrose, H L; Zhao, C et al. (2011) Adult neurogenesis and neurite outgrowth are impaired in LRRK2 G2019S mice. Neurobiol Dis 41:706-16
Angeles, Dario C; Gan, Bong-Hwa; Onstead, Luisa et al. (2011) Mutations in LRRK2 increase phosphorylation of peroxiredoxin 3 exacerbating oxidative stress-induced neuronal death. Hum Mutat 32:1390-7
Finch, N; Carrasquillo, M M; Baker, M et al. (2011) TMEM106B regulates progranulin levels and the penetrance of FTLD in GRN mutation carriers. Neurology 76:467-74

Showing the most recent 10 out of 71 publications